natgillin/translations-raw huggingface dataset:
Having too low or too high blood sugar can affect your ability to drive or use any tools or machines.
Príliš nízka (hypoglykémia) alebo príliš vysoká (hyperglykémia) hladina cukru v krvi môže ovplyvniť schopnosť viesť vozidlá, používať akékoľvek nástroje, alebo obsluhovať akékoľvek stroje.
Having too low or too high blood sugar can affect your ability to drive or use any tools or machines.
Príliš nízka (hypoglykémia) alebo príliš vysoká (hyperglykémia) hladina cukru v krvi môžu ovplyvniť schopnosť viesť vozidlá, používať akékoľvek nástroje, alebo obsluhovať akékoľvek stroje.
Having too low or too high blood sugar or sight problems can affect your ability to drive and use tools or machines.
Príliš nízka alebo príliš vysoká hladina cukru v krvi alebo problémy so zrakom môžu mať vplyv na vašu schopnosť viesť vozidlá a používať náradia či obsluhovať stroje.
Having trouble sleeping (insomnia).
Problémy so spánkom (nespavosť).
Having trouble sleeping;
problémy so spánkom,
Having vaccines while you are taking Xaluprine
Očkovanie počas užívania lieku Xaluprine
Hay-on-Wye Hereford, HR3 5PG United Kingdom
Hay-on-Wye Hereford, HR3 5PG Veľká Británia
Hay-on-Wye HR3 5PG United Kingdom
Hay-on-Wye HR3 5PG Veľká Británia
hayfever
enná nádcha,
Hazard
Hazard ratio
Hazard Ratio
Pomer rizika
Hazard ratio
Pomer rizika 95 % CI
Hazard ratio
Pomer rizík
Hazard ratio (95 % C.I.)
Pomer rizík (95 % C.I.)
Hazard ratio (95 % C.I.)
Pomer rizík (95 % CI)
Hazard ratio (95 % C.I.)
Pomer rizík (95% C.I.)
Hazard ratio (95 % C.I.)
Pomer rizík (95% CI)
Hazard ratio (95 % CI)
Hazard ratio (95 % IS)
Hazard ratio (95 % CI)
Miera rizika (95 % CI)
Hazard ratio (95 % CI)
Pomer rizika (95 % CI)
Hazard ratio (95 % CI)
Pomer rizika (95% CI)
Hazard ratio (95 % CI) b, c
Miera rizika (95 % CI) b, c
Hazard Ratio (95 % CI) p-value b)
Hazard Ratio (95 % CI) p-hodnota b)
Hazard ratio (95 % CI)b, c
Miera rizika (95 % CI)b, c
Hazard ratio (95% C.I.)
Hazard ratio (95 % IS)
Hazard ratio (95% C.I.)
Pomer rizík (95 % CI)
Hazard ratio (95% CI)
(1,041-1,606)
Hazard ratio (95% CI)
(26,4-37,3)
Hazard ratio (95% CI)
(95 % CI)
Hazard ratio (95% CI)
(95 % IS)
Hazard ratio (95% CI)
95 % IS
Hazard ratio (95% CI)
Hazard ratio (95 % IS)
Hazard ratio (95% CI)
Hazard ratio (95% IS)
Hazard Ratio (95% CI)
HR (95% CI)
Hazard ratio (95% CI)
Miera rizika (95 % CI)
Hazard ratio (95% CI)
Pomer rizika
Hazard ratio (95% CI)
Pomer rizika (95 % CI)
Hazard Ratio (95% CI)
Pomer rizika (95 % IS)
Hazard ratio (95% CI)
Pomer rizika (95% CI)
Hazard Ratio (95% CI)
Pomer rizika (95% IS)
Hazard ratio (95% CI)
Pomer rizík (95 % CI)
Hazard ratio (95% CI)
Pomer rizík (95 % IS)
Hazard ratio (95% CI)
Pomer rizík (95% CI)
Hazard Ratio (95% CI)
Pomer rizík (95% IS)
Hazard ratio (95% CI)
Priemerný pomer
Hazard Ratio (95% CI)
Rizikový pomer (95 % CI)
Hazard Ratio (95% CI)
Rizikový pomer (95 % CIS)
Hazard ratio (95% CI)
Stratifikovaný pomer rizika (95% CI)
Hazard Ratio (95% CI)
Štatistická miera rizika (Hazard Ratio) (95% IS)
Hazard Ratio (95% CI) 2
Hazard Ratio (95% IS) 2
Hazard ratio (95% CI) b
Hazard ratio (95% IS)b
Hazard ratio (95% CI) from stratified Cox model
Pomer rizika (95% IS) podľa stratifikovaného Coxovho modelu.
Hazard Ratio (95% CI), p- value
Hazard Ratio (95 % IS), p-hodnota
Hazard Ratio (95% CI)3
Pomer rizika (95 % CI)3
Hazard Ratio (95% CI)4
Hazard Ratio (95 % IS)4
Hazard Ratio (95% CI)a
HR (95% CI)a
Hazard ratio (95% CI)b
Hazard ratio (95% IS)b
Hazard ratio (95% CI)b
Pomer rizík (95 % CI) b
Hazard ratio (95% CI)b
Pomer rizík (95 % CI)b
Hazard ratio (95% CI)b 0.646 (0.543; 0.768)
Hazard ratio (95 % IS)b 0,646 (0,543; 0,768)
Hazard ratio (95% CI)b 0.740 (0.638; 0.859)
Hazard ratio (95 % IS)b 0,740 (0,638; 0,859)
Hazard Ratio (95% CI)b lenvatinib + everolimus vs everolimus
Pomer rizík (95% CI)b lenvatinib + everolimus vs everolimus
Hazard ratio (95% CI)b, e
Miera rizika (95 % CI) b, e
Hazard ratio (95% CI)b,c
Miera rizika (95 % CI)b,c
Hazard ratio (95% CI)c
Miera rizika (95 % CI)c
Hazard ratio (95% CI)c p-valued
Hazard ratio (95 % CI)c p-hodnota (d)
Hazard ratio (95% CI)c p-valued
Hazard ratio (95 % CI)c p-hodnotad
Hazard ratio (95% CI)c p-valued
Miera rizika (95 % CI)c p-hodnotad
Hazard Ratio (95% CI)†
Pomer rizika (95% CI)
Hazard ratio (95%CI)
(95% IS)
Hazard ratio (95%CI)
Hazard ratio (95% IS)
Hazard Ratio (95%CI)
Pomer rizika (95 % IS)
Hazard ratio (95%CI)
Pomer rizika (95% IS)
Hazard ratio (97.5% CI)
Hazard ratio (97,5 % IS)
Hazard ratio (97.5% CI) a
Hazard ratio (97,5 % IS)a
Hazard Ratio (97.5% CI)a
Stupeň rizika (97,5 % CI)a
Hazard ratio (99% CI)b,c
Miera rizika(99 % CI)b,c
Hazard ratio (CI95%)
Pomer rizika (95% CI)
Hazard ratio (CI95%) 3-month Sustained Disability Progression week 108
Pomer rizika (95% CI) Progresia 3 mesačnej trvalej invalidity týždeň 108
Hazard ratio (CI95%) 6-month Sustained Disability Progression week 108
Pomer rizika (95% CI) Progresia 6 mesačnej trvalej invalidity týždeň 108
Hazard Ratio (Gefitinib versus Docetaxel) and 95% CI
HR Pomer rizika (pomer rizika < 1 v prospech IRESSY)
Hazard ratio (HR)
Pomer rizika (HR)
Hazard Ratio (HR) (95% CI)
Pomer rizika (HR) (95 % CI)
Hazard Ratio (HR) (95%CI)
Hazard ratio (HR) (95 % CI)
Hazard ratio (HR) (Catumaxomab versus Catumaxomab + Prednisolone)
Hazard ratio (HR) (katumaxomab verzus katumaxomab + prednizolón)
Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CI c
Pomer rizika (Pom+LD-Dex:HD-Dex) dvojstranný 95 % CIc
Hazard ratio (stratified*)
Pomer rizika (stratifikovaný*)
Hazard ratio (sunitinib vs IFN-) 0.5268
Miera rizika (sunitinib vs IFN-) 0,5268
Hazard ratio (sunitinib vs IFN-) 0.8209
Miera rizika (sunitinib vs IFN-) 0,8209
Hazard Ratio / Odds Ratio
Pomer rizík/Pomer pravdepodobnosti
Hazard ratio 0.45 (95% Cl, 0.22-0.89)
Pomer rizika 0,45 (95% Cl, 0,22-0,89)
Hazard ratio 0.46 (95% Cl, 0.32-0.65)
Pomer rizika 0,46 (95% Cl, 0,32-0,65)
Hazard ratio 0.46, CI95% 0.33; 0.64, p<0.001
Pomer rizika 0,46, CI95% 0,33; 0,64, p<0,001
Hazard ratio 0.58, CI95% 0.43; 0.73, p<0.001
Pomer rizika 0,58, CI95% 0,43; 0,73, p<0,001
Hazard ratio 0.59
Pomer rizika 0,59
Hazard ratio 0.73
Pomer rizika 0,73
Hazard ratio 0.88
Pomer rizika 0,88
Hazard ratio 95% CI
Hazard ratio 95 % IS
Hazard ratio 95% CI
Hazard ratio 95% IS
Hazard ratio 95% CI
Miera rizika 95 % IS
Hazard ratio 95% CI
Miera rizika 95% IS
Hazard ratio 95% CI
PSA** pomer odpovedí ( %) 95 % IS
Hazard ratio 95% CI
PSA** pomer odpovedí( %) 95 % IS
Hazard ratio < 1 favours enzalutamide
Pomer rizík < 1 znamená lepší efekt enzalutamidu
Hazard ratio < 1 favours ZYTIGA
Hazard ratio 1 v prospech lieku ZYTIGA
Hazard Ratio = 0.33 95% CI [0.25, 0.43]
Pomer rizika = 0,33 95% IS [0,25, 0,43]
Hazard Ratio = 0.35 95% CI [0.27, 0.45]
Pomer rizika = 0,35 95% IS [0,27, 0,45]
Hazard Ratio = 0.45 95% CI [0.38, 0.54]
Pomer rizika = 0,45 95% IS [0,38, 0,54]
Hazard Ratio = 0.48 95% CI [0.35, 0.67]
Pomer rizika = 0,48 95% IS [0,35; 0,67]
Hazard ratio [95% CI]
Hazard ratio [95% IS]
Hazard ratio [95% CI]
Miera rizika [95 % IS]
Hazard ratio [95% CI]
Pomer rizika [95 % IS]
Hazard Ratio [95% CI]
Pomer rizík [95 % IS]
Hazard Ratio [95% CI]
Pomer rizík [95% IS]
Hazard Ratio [95% CI] 0.77 [0.61, 0.97]
Pomer rizika [95% CI] 0,77 [0,61; 0,97]
Hazard ratio [95% CI] d: 0.73 [0.53, 1.01]
Pomer rizík [95% IS] d: 0,73 [0,53; 1,01]
Hazard ratio [95% CI] d: 0.78 [0.57, 1.07]
Pomer rizík [95% IS] d: 0,78 [0,57; 1,07]
Hazard ratio [95% CI], p-value a
Pomer rizika [95 % CI], p-hodnota a
Hazard Ratio [97.61% CI] 0.68 [0.55, 0.85]
Pomer rizika [97,61 % CI] 0,68 [0,55; 0,85]
Hazard ratio b (95% CI)
Miera rizika (95 % CI)b
Hazard ratio estimate is based on a Cox’s model stratified by IPI risk and stage of disease.
Odhad hazard ratio je založený na Coxovom modeli stratifikovanom podľa rizika IPI a štádia ochorenia.
Hazard ratio is derived from a stratified proportional hazards model.
Hazard ratio je odvodené zo stratifikovaného proporcionálneho modelu rizika.
Hazard ratio is expressed as treatment/control and estimated from Cox model
Miera rizika je vyjadrená ako liečba/kontrola a odhaduje sa z Coxovho modelu
Hazard ratio over warfarin (95 % CI)
g Pomer rizika voči warfarínu (95 % CI)
Hazard ratio over warfarin (95 % CI)
Pomer rizika voči warfarínu (95 % CI)
Hazard Ratio P Value
Hazard Ratio Hodnota p
Hazard ratio to triamcinolone acetonide
Pomer rizika oproti triamcinolón- acetonidu
Hazard Ratio versus AC→P (95% CI)
Hazard Ratio oproti AC→P (95 % CI)
Hazard Ratio versus Observation
Pomer rizík oproti pozorovaniu
Hazard Ratio vs placebo (95% confidence interval)
Pomer rizika voči placebu (95 % interval spoľahlivosti)
Hazard ratio vs placebo arm (95% CI)
Hazard ratio oproti skupine s placebom (95 % IS)
Hazard ratio vs warfarin (95% confidence interval)
Pomer rizika voči warfarínu (95 % interval spoľahlivosti)
Hazard ratio vs. warfarin (95 % CI)
Pomer rizika voči
Hazard ratio vs. warfarin (95 % CI)
Pomer rizika voči warfarínu (95 % CI)
Hazard ratio vs. warfarin (95 % CI)
Pomer rizika voči warfarínu (95% CI)
Hazard ratio vs. warfarin (95% confidence interval)
Pomer rizika voči warfarínu (95 % interval spoľahlivosti)
Hazard ratio with 95% confidence interval log-rank test
Miera rizika s 95 % intervalom spoľahlivosti log-rank test
Hazard ratio# *
Pomer rizík#
Hazard ratio*
Pomer rizík
Hazard ratio* (95% CI)
Pomer rizika* (95 % IS)
Hazard ratio* (95% CI)
Pomer rizika* (95% IS)
Hazard ratio** (95% CI) 0.425 (0.347; 0.522)
Hazard ratio** (95 % IS)
Hazard ratio** (95% CI) 0.752 (0.606; 0.934)
Hazard ratio** (95 % IS)
Hazard ratio** (95% CI) 0.806 (0.697; 0.931)
Hazard ratio** (95 % IS) 0,806 (0,697; 0,931)
Hazard ratio3
Pomer rizika3
Hazard ratio3
Pomer rizík3
Hazard ratio3
Pomer rizíka3
Hazard ratio: (95% CI)
(95 % IS)
Hazard ratio: (95% CI)
Hazard ratio (95 % IS)
Hazard ratio: (95% CI)
Hazard ratio: (95 % CI)
Hazard ratio: (95% CI)
Hazard ratio: (95 % IS)
Hazard ratio: (95% CI)
Hazard ratio: (95% IS)
Hazard ratio: (95% CI)
Upravený hazard ratio (95 % IS)
Hazard Ratio: 1.032
Hazard ratio: 1,032
Hazard ratio: 1.122
Hazard ratio: 1,032
Hazard ratio: 1.122
Hazard ratio: 1,122
Hazard Ratioa (95% CI), p- valueb
Hazard Ratioa (95 % IS), p-hodnotab
Hazard ratioa 0.73 (95.92% CI) (0.59, 0.89) p-valueb 0.0015
Pomer rizikaa 0,73 (95,92 % CI) (0,59; 0,89) p-hodnotab 0,0015
Hazard ratiob (95% CI)
>=90 % n (%)
Hazard ratiob (95% CI)
CR+PRf n (%)
Hazard ratiob (95% CI)
Miera rizikab (95 % CI)
Hazard ratiob (95% CI)
Miera rizikab (95 % IS)
Hazard ratiob (95% CI)
Miera rizikab (95% IS)
Hazard ratios of progression-free survival according to Binet stage (ITT) – 48.1 months median observation time
Hodnoty hazard ratio pre prežívanie bez progresie ochorenia podľa štádia ochorenia podľa Bineta (ITT) - medián obdobia sledovania bol 48,1 mesiaca
Hazard ratios of progression-free survival according to Binet stage (ITT) – 48.1 months median observation time
Štatistické miery rizika prežívania bez progresie ochorenia podľa Binet štádia (ITT) – medián času prežívania 48,1 mesiaca
Hazard ratios of progression-free survival according to Binet stage (ITT) – 48.1 months median observation time
Štatistické miery rizika prežívania bez progresie ochorenia podľa Binet štádia (ITT)-medián času prežívania 48,1 mesiaca
Hazard ratios were calculated post- hoc; for all CV events, HR=0.91 (95% CI, 0.62 to 1.34); for MACE, HR=0.52 (95% CI, 0.31 to 0.90).
Pomery rizík (HR) boli vypočítané následne; pre všetky KV príhody, HR = 0,91 (95 % CI, 0,62 až 1,34); pre MACE, HR = 0,52 (95 % CI, 0,31 až 0,90).
Hazard Ratio†,‡ (95% CI)
Pomer rizika†,‡ (95% IS)
Hazard/Odds ratio
Riziko/pomer pravdepodobnosti
HbA1c (%)
213
HbA1c (%)
HbA1c ( %)
HbA1c (%) at end of treatment
HbA1c (%) na konci liečby
HbA1c (%) at week 121
HbA1c (%) v 12. týždni1
HbA1c (%) at week 18
HbA1c (%) v 18. týždni
HbA1c (%) at week 18a
HbA1c (%) v 18. týždnia
HbA1c (%) at week 24
v 24. týždni
HbA1c (%) at week 24*
HbA1c (%) v 24. týždni
HbA1c (%) at week 241
HbA1c (%) v 24. týždni1
HbA1c (%) at week 522
HbA1c (%) v 52. týždni2
HbA1c (%) at week 52b
HbA1c (%) v 52. týždnib
HbA1c (%) at week 78
HbA1c (%) v 78. týždni
HbA1c (%) change from base line
HbA1c(%) zmena oproti východiskovej hodnote
HbA1c at week 24 in active-controlled study comparing the combination of saxagliptin and dapagliflozin added concurrently to metformin with either saxagliptin or dapagliflozin added to metformin
HbA1c v 24. týždni v aktívne kontrolovanej štúdii porovnávajúcej kombináciu saxagliptínu a dapagliflozínu pridanú súbežne k metformínu, oproti saxagliptínu alebo dapagliflozínu pridanému k metformínu
HbA1c change from baseline at week 24 excluding data after rescue for randomized subjects – studies MB102129 and CV181168
Zmena HbA1c od východiskovej hodnoty v 24. týždni s vylúčením údajov po záchrannej liečbe randomizovaných osôb– štúdie MB102129 a CV181168
HbA1c changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM versus 4.1 mM.
Zmeny HbA1c z východiskovej hodnoty boli v obidvoch liečených skupinách podobné; hodnoty hladiny glukózy v krvi zaznamenané počas noci boli významne vyššie v skupine inzulín glargín / lispro ako v skupine NPH/bežný ľudský inzulín, s priemernou najnižšou hodnotou (nadir) 5,4 mmol/l oproti 4,1 mmol/l.
HbA1c changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM vs.
Zmeny HbA1c z východiskovej hodnoty boli v obidvoch liečených skupinách podobné; hodnoty hladiny glukózy v krvi zaznamenané počas noci boli významne vyššie v skupine inzulín glargínom / lispro ako v skupine NPH/bežný ľudský inzulín, s priemernou najnižšou hodnotou (nadir) 5,4 mmol/l oproti 4,1 mmol/l.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c je ukazovateľom kontroly hladiny glukózy v krvi.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c je ukazovateľom miery kontroly hladiny glukózy v krvi.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c je ukazovateľom regulácie hladiny glukózy v krvi.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c je ukazovateľom toho, do akej miery je glukóza v krvi kontrolovaná.
HbA1c gives an indication of how well the blood glucose is controlled.
Hladiny HbA1c udávajú, do akej miery je glukóza v krvi kontrolovaná.
HbA1c is a substance in the blood which gives an indication of how well the blood glucose is controlled.
HbA1c látka v krvi, ktorá je ukazovateľom kontroly hladiny glukózy v krvi.
HbA1c levels give an indication of how well the blood glucose is controlled.
Hladiny HbA1c sú ukazovateľmi toho, do akej miery je kontrolovaná hladina glukózy v krvi.
HbA1c levels give an indication of how well the blood glucose is controlled.
Hladiny HbA1c sú ukazovateľmi toho, do akej miery je regulovaná hladina glukózy v krvi.
HbA1c levels give an indication of how well the blood glucose is controlled.
Hladiny HbA1c udávajú, do akej miery je glukóza v krvi kontrolovaná.
HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
Hladiny HbA1c boli počas šesťmesačnej liečby liekom Actrapid stabilné.
HbA1c levels were around 8% at the start of the study.
Na začiatku štúdie boli hladiny HbA1c okolo 8 %.
HbA1c levels were measured after 12 weeks when Lyxumia was used alone and after 24 weeks when it was used in combination with other diabetes medicines.
Hladiny HbA1c sa merali po 12 týždňoch, ak sa liek Lyxumia používal samostatne, a po 24 týždňoch, ak sa používal v kombinácii s inými liekmi proti cukrovke.
HbA1c levels were measured after 26 weeks in the first study and 52 weeks in the second study.
Hladiny HbA1c sa merali po 26 týždňoch v prvej štúdii a po 52 týždňoch v druhej štúdii.
HbA1c levels were measured after 26 weeks when Vipidia was used alone or added to other diabetes medicines, and after 52 weeks when Vipidia was compared with glipizide or pioglitazone.
Hladiny HbA1c sa merali po 26 týždňoch, keď sa liek Vipidia používal samostatne alebo sa pridával k iným liekom proti cukrovke a po 52 týždňoch, keď sa liek Vipidia porovnával s glipizidom alebo pioglitazónom.
HbA1c levels were on average around 9% at the start of the study.
Na začiatku štúdie boli hladiny HbA1c priemerne okolo 9 %.
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Januvia to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Hladiny HbA1c sa po 18 týždňoch znížili o 1,03 % u pacientov, ktorí užívali metformín a rosiglitazón s pridaným liekom Januvia v porovnaní so znížením o 0,31 % u pacientov, ktorým bolo k liečbe pridané placebo.
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Ristaben to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Hladiny HbA1c sa znížili o 1,03 % po 18 týždňoch v prípade pacientov, ktorým sa pridal liek Ristaben k metformínu a roziglitazónu, v porovnaní so znížením o 0,31
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Tesavel to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Hladiny HbA1c sa po 18 týždňoch znížili o 1,03 % u pacientov, ktorí užívali metformín a rosiglitazón s pridaným liekom Tesavel v porovnaní so znížením o 0,31 % u pacientov, ktorým bolo k liečbe pridané placebo.
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Xelevia to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Hladiny HbA1c sa po 18 týždňoch znížili o 1,03 % u pacientov, ktorí užívali metformín a rosiglitazón s pridaným liekom Xelevia v porovnaní so znížením o 0,31 % u pacientov, ktorým bolo k liečbe pridané placebo.
HbA1c reductions were seen across subgroups including gender, age, race, duration of disease, and baseline body mass index (BMI).
Zníženia HbA1c sa pozorovali vo všetkých podskupinách vrátane pohlavia, veku, rasy, dĺžky trvania ochorenia a východiskovej hodnoty indexu telesnej hmotnosti (body mass index, BMI).
HbA1c subgroup analysis by baseline HbA1c at week 24 in randomized subjects
HbA1c analýza podskupiny podľa východiskovej hodnoty HbA1c v 24. týždni u randomizovaných osôb
HbA1c was stable in both duloxetine-treated and placebo-treated patients.
Hodnoty HbA1c boli stabilné aj u pacientov liečených duloxetínom aj u pacientov s placebom.
HbA1c weight (%) (%) <7.0% (%) ≤6.5% (%) (mmol/L) (kg)
Pacienti s cieľ. hodnotou HbA1c
HbA1c weight (%) (%) <7.0% (%) ≤6.5% (%) (mmol/L) (kg)
Telesná hmotnosť alebo index telesnej hmotnosti
HBeAg loss5
Vymiznutie HBeAg5
HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted in cumulative response rates of 94% for HBV DNA < 300 copies/ml by PCR and 89% for ALT normalisation versus 77% for HBV DNA < 300 copies/ml by PCR and 84% for ALT normalisation for lamivudine-treated patients (n = 313).
HBeAg negatívni pacienti (štúdia 027): liečba entekavirom po dobu až 96 týždňov (n = 325) viedla ku kumulatívnej miere odpovedí v hodnote 94 % pre HBV DNA < 300 kópií/ml metódou PCR a 89 % pre normalizáciu ALT oproti 77 % pre HBV DNA < 300 kópií/ml metódou PCR a 84 % pre normalizáciu ALT u pacientov liečených lamivudínom (n = 313).
HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted in cumulative response rates of 94% for HBV DNA < 300 copies/ml by PCR and 89% for ALT normalisation versus 77% for HBV DNA < 300 copies/ml by PCR and 84% for ALT normalisation for lamivudine-treated patients (n = 313).
HBeAg negatívni pacienti (štúdia 027): liečba entekavirom po dobu až 96 týždňov (n = 325) viedla ku kumulatívnej miere odpovedí v hodnote 94 % pre HBV DNA < 300 kópií/ml metódou PCR a 89 % pre normalizáciu ALT oproti 77% pre HBV DNA < 300 kópií/ml metódou PCR a 84 % pre normalizáciu ALT u pacientov liečených lamivudínom (n = 313).
HBeAg Positive (study 022)
HBeAg pozitívni (štúdia 022)
HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354) resulted in cumulative response rates of 80% for HBV DNA < 300 copies/ml by PCR, 87% for ALT normalisation, 31% for HBeAg seroconversion and 2% for HBsAg seroconversion (5% for HBsAg loss).
HBeAg pozitívni pacienti (štúdia 022): liečba entekavirom po dobu až 96 týždňov (n = 354) viedla ku kumulatívnej miere odpovedí v hodnote 80 % pre HBV DNA < 300 kópií/ml metódou PCR, 87 % pre normalizáciu ALT, 31 % pre HBeAg sérokonverziu a 2 % pre HBsAg sérokonverziu (5 % pre stratu HBsAg).
HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354) resulted in cumulative response rates of 80% for HBV DNA < 300 copies/ml by PCR, 87% for ALT normalisation, 31% for HBeAg seroconversion and 2% for HBsAg seroconversion (5% for HBsAg loss).
HBeAg pozitívni pacienti (štúdia 022): liečba entekavirom po dobu až 96 týždňov (n = 354) viedla ku kumulatívnej miere odpovedí v hodnote 80 % pre HBV DNA < 300 kópií/ml metódou PCR, 87 % pre normalizáciu ALT, 31 % pre HBeAg sérokonverziu a 2% pre HBsAg sérokonverziu (5% pre stratu HBsAg).
HBeAg positive (study 026)
HBeAg pozitívni (štúdia 026)
HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141) resulted in cumulative response rates of 30% for HBV DNA < 300 copies/ml by PCR, 85% for ALT normalisation and 17% for HBeAg seroconversion.
HBeAg pozitívni pacienti (štúdia 026): liečba entekavirom po dobu až 96 týždňov (n = 141) viedla ku kumulatívnej miere odpovedí v hodnote 30 % pre HBV DNA < 300 kópií/ml metódou PCR a 85 % pre normalizáciu ALT a 17 % pre HBeAg sérokonverziu.
HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease.
HBeAg pozitívnou a HBeAg negatívnou chronickou hepatitídou B s kompenzovaným ochorením pečene.
HBeAg Sero- conversion
HBeAg sérokonverzia
HBeAg Seroconversion
HBeAg Sérokonverzia
HBeAg seroconversion
sérokonverzia HBeAg
HBeAg seroconversion and loss assessed only in patients with detectable HBeAg at baseline.
Sérokonverzia a vymiznutie HBeAg vyhodnotené len u pacientov s dokázateľným východiskovým HBeAg.
HBeAg seroconversion n/N (%)
Sérokonverzia HbeAg n/N (%)
HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT > 2 x ULN seroconverted.
Miera sérokonverzie bola zvýšená u pacientov so zvýšenými hladinami ALT; sérokonverzia nastala u 77 % (20/26) pacientov s hodnotou ALT pred liečbou > 2 x UNL.
HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT > 2 x ULN seroconverted.
Miera sérokonverzie HBeAg bola zvýšená u pacientov so zvýšenými hladinami ALT; sérokonverzia nastala u 77 % (20/26) pacientov s hodnotou ALT pred liečbou > 2 x UNL.
HBeAg seroconversion4
Sérokonverzia HBeAg4
HBeAg seroconversiona
HBeAg sérokonverziaa
HBeAg-negative
HBeAg-negatívni
HBeAg-negative (n = 446)
HBeAg-negatívni (n = 446)
HBeAg-negative patients (n = 209*)
HBeAg-negatívni pacienti (n = 209*)
HBeAg-negative patients: The mean age of patients was 43 years, 79% were male, 65% were Asian, 23% were Caucasian, and 11% had previously received alfa-interferon therapy.
HBeAg-negatívni pacienti: Priemerný vek pacientov bol 43 rokov, 79 % bolo mužov, 65 % Ázijcov, 23 % belochov a 11 % dostalo predtým liečbu interferónom alfa.
HBeAg-positive
HBeAg-pozitívni
HBeAg-positive (n = 921)
HbeAg-pozitívni (n = 921)
HBeAg-positive patients (n = 293*)
HBeAg-pozitívni pacienti (n = 293*)
HBeAg-positive patients: The mean age of patients was 32 years, 74% were male, 82% were Asian, 12% were Caucasian, and 6% had previously received alfa-interferon therapy.
HBeAg-pozitívni pacienti: Priemerný vek pacientov bol 32 rokov, 74 % bolo mužov, 82 % Ázijcov, 12 % belochov a 6 % dostalo predtým liečbu interferónom alfa.
HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell.
HbF zasahuje do procesu polymerizácie HbS a tak bráni, aby sa červená krvinka sformovala do kosáčikovitého tvaru.
HBM Pharma s.r.o.
HBM Pharma s.r.o
HBsAg is produced by culture, in a selective medium, of genetically engineered yeast cells.
HBsAg je pripravovaný kultiváciou v selektívnom médiu kultúr geneticky upravených kvasiniek.
HBsAg loss/ seroconversion
HBsAg úbytok/séro- konverzia